HELX vs. IBB
Compare and contrast key facts about Franklin Genomic Advancements ETF (HELX) and iShares Nasdaq Biotechnology ETF (IBB).
HELX and IBB are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. HELX is an actively managed fund by Franklin Templeton. It was launched on Feb 25, 2020. IBB is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology Index. It was launched on Feb 5, 2001.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HELX or IBB.
Key characteristics
| HELX | IBB | |
|---|---|---|
| YTD Return | 2.43% | 9.21% |
| 1Y Return | 17.11% | 25.34% |
| 3Y Return (Ann) | -15.12% | -1.80% |
| Sharpe Ratio | 0.91 | 1.35 |
| Sortino Ratio | 1.39 | 1.96 |
| Omega Ratio | 1.16 | 1.23 |
| Calmar Ratio | 0.29 | 0.68 |
| Martin Ratio | 3.78 | 6.35 |
| Ulcer Index | 4.18% | 3.69% |
| Daily Std Dev | 17.32% | 17.33% |
| Max Drawdown | -56.33% | -62.85% |
| Current Drawdown | -46.27% | -15.21% |
Correlation
The correlation between HELX and IBB is 0.86, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
HELX vs. IBB - Performance Comparison
In the year-to-date period, HELX achieves a 2.43% return, which is significantly lower than IBB's 9.21% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
HELX vs. IBB - Expense Ratio Comparison
HELX has a 0.50% expense ratio, which is higher than IBB's 0.47% expense ratio.
Risk-Adjusted Performance
HELX vs. IBB - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Franklin Genomic Advancements ETF (HELX) and iShares Nasdaq Biotechnology ETF (IBB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
HELX vs. IBB - Dividend Comparison
HELX has not paid dividends to shareholders, while IBB's dividend yield for the trailing twelve months is around 0.30%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
HELX Franklin Genomic Advancements ETF | 0.00% | 0.00% | 0.00% | 0.24% | 0.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
IBB iShares Nasdaq Biotechnology ETF | 0.30% | 0.26% | 0.31% | 0.21% | 0.20% | 0.17% | 0.19% | 0.30% | 0.19% | 0.03% | 0.15% | 0.03% |
Drawdowns
HELX vs. IBB - Drawdown Comparison
The maximum HELX drawdown since its inception was -56.33%, smaller than the maximum IBB drawdown of -62.85%. Use the drawdown chart below to compare losses from any high point for HELX and IBB. For additional features, visit the drawdowns tool.
Volatility
HELX vs. IBB - Volatility Comparison
Franklin Genomic Advancements ETF (HELX) and iShares Nasdaq Biotechnology ETF (IBB) have volatilities of 4.33% and 4.21%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.